AngioDynamics Balanced Scorecard
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Go Beyond the Preview – Access the Full Balanced Scorecard
This AngioDynamics Balanced Scorecard Analysis gives you a clear, company-specific view of performance across financial, customer, internal process, and learning and growth priorities. The page already shows a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Benefits
Focused Therapy Map
A focused therapy map lets AngioDynamics tie FY2025 results by line, so peripheral vascular disease, oncology, and other non-vascular areas do not get blurred into one average. It shows which therapy line is winning adoption, carrying margin, and adding strategic momentum. That helps leaders spot where revenue mix is improving and where execution still lags.
Adoption Tracking
In FY2025, AngioDynamics reported about $307 million in net sales, so adoption tracking can show whether angioplasty, thrombolysis, and embolization tools are moving from first use to repeat use. It gives managers a cleaner read on conversion by physician group, not just shipments. One extra procedure per account can matter more than one-time trials.
Quality Control
Quality control matters at AngioDynamics because buyers in minimally invasive care watch reliability, safety, and FDA discipline closely. In FY2025, the scorecard should link complaint rate, on-time delivery, and product defect rate to growth targets, since one failure can hurt trust fast. With medical device recalls still a live risk, tight process control protects both margins and repeat orders.
Clinical Education
Clinical education is a key lever for AngioDynamics, because physician training drives adoption of its minimally invasive products and helps turn awareness into repeat procedure volume. In a balanced scorecard, the company can track 2025 metrics such as training completion rates, case support, and follow-up engagement to see whether education is converting into use. That matters because even small gains in procedural adoption can support sales in a business that reported about $300 million in annual net sales in fiscal 2025.
Cross-Functional Alignment
Cross-functional alignment matters at AngioDynamics because R&D, regulatory, manufacturing, and commercial teams must move together across a 2025 revenue base near $300 million. A balanced scorecard links launch timing, inventory, and sales execution across multiple device lines, so teams can cut handoff delays and avoid stock mismatches. That matters when even small slips can hurt a company already managing low-margin operations and tight working capital.
AngioDynamics: Turning $307M Sales Into Repeat-Use Growth
For AngioDynamics, a balanced scorecard turns FY2025 sales of about $307 million into clearer action by linking therapy adoption, quality, and training to growth. It helps leaders see which product lines convert first use into repeat procedures, where complaints or defects could hurt trust, and where education lifts case volume. It also aligns R&D, manufacturing, and sales so launches and inventory stay in step.
| FY2025 metric | Use in scorecard |
|---|---|
| $307 million | Growth baseline |
| Adoption rate | Repeat-use signal |
| Complaint rate | Quality risk control |
What is included in the product
Detailed Word Document
Editable Excel File
Drawbacks
KPI Overload
KPI overload can slow AngioDynamics because a scorecard that tracks quality, sales, training, and finance at once gets crowded fast. In FY2025, a small team can't afford to spend hours on reporting when every launch and adoption step matters. If 10 people add just 5 hours a week to KPI admin, that is 2,600 hours a year lost to paperwork.
Reimbursement Lag
Reimbursement lag can hide real progress at AngioDynamics: training, site activation, and pipeline work can improve while angioplasty or embolization volumes stay soft until payers and hospital budgets catch up. In fiscal 2025, AngioDynamics reported net sales of about $300 million, showing how slow procedure adoption can still weigh on the scorecard even when commercial activity looks better. If coverage stays delayed, the gap between leading metrics and billed cases can stretch for several quarters.
Adoption Noise
Adoption Noise is a real risk for AngioDynamics because physicians may use a product, but hospitals still control the purchase order, so demand can look stronger than it is. With fiscal 2025 net sales in the low $300 million range, even one stocking run or a single trial program can distort the trend. That makes it hard to separate steady clinical pull from temporary inventory builds or one-off surgeon interest.
Evidence Gap
AngioDynamics' scorecard can look better than the evidence base if it counts launches and regulatory wins more than clinical proof. In fiscal 2025, the real test was still whether peer-reviewed data and real-world outcomes could support durable physician trust and repeat use. Without that, even a successful product launch can leave sales, margin, and adoption under pressure.
Portfolio Masking
Portfolio masking is a real risk for AngioDynamics because one scorecard can blur vascular, oncology, and non-vascular results. In FY2025, net sales were about $286 million, so a stronger franchise can easily offset weakness elsewhere and still look fine at the company level. That can hide where product mix is slipping and where margin pressure is really building.
AngioDynamics' Scorecard May Look Stronger Than Reality
AngioDynamics' balanced scorecard can overstate progress because FY2025 net sales were $286.3 million, yet adoption and reimbursement still move slower than launches. KPI-heavy tracking also adds drag for a small team, so reporting can crowd out selling time. Portfolio mix can hide weakness in slower franchises, making the picture look cleaner than it is.
| Drawback | FY2025 data point | Why it matters |
|---|---|---|
| Reimbursement lag | Net sales: $286.3 million | Sales can trail activity |
| Portfolio masking | Low $300 million revenue base | Weak spots get hidden |
Get Your Copy
AngioDynamics Reference Sources
This is the actual AngioDynamics Balanced Scorecard analysis document you'll receive after purchase – no samples, just the real file. The preview you see here is taken directly from the full report, so you're viewing the same content included in your download. Once purchased, the complete, detailed Balanced Scorecard analysis becomes available immediately.
Frequently Asked Questions
It emphasizes balancing clinical adoption, quality, and capital discipline. For AngioDynamics, that means watching 3 therapy areas, 2 core physician groups, and 3 procedure families such as angioplasty, thrombolysis, and embolization. The best scorecard ties those indicators to revenue mix, complaint trends, and training completion.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.